Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals

Shu, Zhanjun; Chen, Yuying; Abudureyimu, Aihemaiti; Li, Tingting; Yuan, Ting; Ma, Jianping; Li, Xiaochun; Ma, Xiao; Jang, Chengyuan; Bao, Gang; Sun, Binlian; Yang, Rongge

doi:10.1007/s00705-018-3825-7

Cited by 15 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, V106M/I/A, K103N and V179D/E/T/L were the rst three common mutations associated with NNRTIs resistance while M184V/I, D67N/G/S/H and K65R/N were the rst three common mutations associated with NRTIs. These mutations were also high-frequency reported previous literatures [18, [30][31][32].…”

Section: Discussionsupporting

confidence: 80%

Genetic characterization of HIV-1 viruses among antiretroviral therapy failure individuals in Suzhou City, China

Dong

TIAN

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: This retrospective study was aimed to characterize the distribution of HIV-1 genotypes and prevalence of drug-resistance mutations in antiretroviral therapy (ART) failure individuals in Suzhou City, China. Methods: Polgene of HIV-1 viruses in EDTA anticoagulant plasma samples of 398 ART failure HIV-infected individuals were successfully amplified by using an in-house assay. Drug resistance mutations were analyzed by using the Stanford HIV Drug Resistance Database system (https://hivdb.stanford.edu/hivdb/by-mutations/). HIV-1 genotypes were determined by REGA HIV subtyping tool (version 3.46, https://www.genomedetective.com/app/typingtool/hiv). Near full-length genomes (NFLG) of HIV-1 viruses were obtained by next generation sequencing method. Results: Sequences analysis of the pol gene revealed that CRF 01_AE (57.29%, 228/398) was the dominant subtype circulating in Suzhou City, followed by CRF 07_BC (17.34%, 69/398), subtype B (7.54%, 30/398), CRF 08_BC (6.53%, 26/398), CRF 67_01B (3.02%, 12/398) and CRF55_01B (2.51%, 10/398). The overall prevalence of drug-resistant mutations in ART failure HIV-infected individuals was 64.57% (257/398), including 45.48% (181/398) for nucleotide reverse transcriptase inhibitors (NRTIs) mutations, 63.32% (252/398) for non-nucleoside reverse transcriptase inhibitors (NNRTIs) mutations, and 3.02% (12/398) for protease inhibitors (PIs) mutations. Ten near full-length genomes (NFLG) of HIV-1 viruses were identified, including six recombinants of CRF 01_AE and subtype B, two recombinants of CRF 01_AE, subtype B and subtype C sequences, one recombinant of CRF 01_AE and subtype C and one recombinant of CRF 01_AE, subtype A1 and subtype C. Conclusions: The high prevalence of drug-resistant HIV-1 viruses was a serious challenge for HIV prevention and HIV-infected individuals’ treatment. Therapeutic regimens of ART failure HIV-infected individuals should be adjusted in time according to drug resistance test results. NFLG sequencing facilitates the identification of new HIV-1 recombinant strains.

show abstract

Section: Discussionsupporting

confidence: 80%

Genetic characterization of HIV-1 viruses among antiretroviral therapy failure individuals in Suzhou City, China

Dong

TIAN

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Chengdu is an area with predominance of CRF01_AE and CRF08_BC, indicating distinct heterogeneity compared to what has been shown in other regions [18,19]. For instance, about half of the subtypes were identified as CRF08_BC (47.4%) among the recently infected population in Yunnan [20] and CRF07_BC was the predominant strain in Xinjiang Province [21]. However, CRF01_AE was dominant in east China [22,23].…”

Section: Discussionmentioning

confidence: 85%

HIV‐1 Drug Resistance, Distribution of Subtypes, and Drug Resistance‐Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014‐2016

Chen

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The National Free Antiretroviral Therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which has acted as an efficient method to suppress viral replication and helps prevent onward transmissions. But the problems of HIV drug resistance (HIVDR) may also come along. There is little data on the prevalence of HIVDR in Chengdu, where the number of HIV/AIDS patients ranks first among provincial capitals. Therefore, epidemiological surveillance was conducted in this area. From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least six months were enrolled. Demographic, behavioral information and medical history were recorded, and blood samples were collected for viral loads and immune cell count analyses. HIV-1 pol was obtained for HIV-1 subtypes and drug resistance-associated mutations (DRMs) among virologic failure patients. A total of 13,782 individuals were enrolled, and 481 samples were sequenced for subtypes and drug resistance analysis. Six subtypes were identified, among which CRF01_AE (54.3%) and CRF07_BC (41.6%) were the dominant subtypes, and CRF55_01B (0.4%) was detected in Chengdu for the first time. The prevalence of HIVDR in treatment-experienced patients was 1.8%, with 1.2% to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs), and 0.14% to protease inhibitors (PIs). The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs. This study focused on the HIVDR surveillance among patients receiving treatment in Chengdu. The overall prevalence of HIVDR was relatively low among treated patients. These findings were believed to be contributed to an understanding of HIV-1 subtypes, HIVDR prevalence, and DRMs in Chengdu and thereby optimizing clinical management, prevention, and control of HIV.

show abstract

“…The overall prevalence of DR studied subjects in 2014-2016 was 1.8% in Chengdu. The rate was relatively lower than that in other areas of China, such as Xinjiang, Yunnan and Jiangsu, and also lower than average rate of Sichuan [22,23,29,30]. However, the rate varies a lot from previous reports in Chengdu, which reported that 17% (27/159) The Chengdu ART regimen includes 3TC, one NRTI (AZT/D4T/TDF) and one NNRTI (EFV/NVP).…”

Section: Categories Of Antiretroviral Drugs and Susceptibility Of Drumentioning

confidence: 71%

“…In total, 1.2% of the samples were resistant to nucleoside reverse transcriptase inhibitors (NRTIs), Phylogenetic analysis identified four recombinant subtypes CRF01_AE, CRF07_BC, CRF08_BC, CRF55_01B and two subtypes B, C. Chengdu is an area with predominance of CRF01_AE and CRF08_BC, indicating a distinct subtypic heterogeneity compared to what has been shown in other regions [20,21]. For instance, about half of the subtypes were identified as CRF08_BC (47.4%) among the recently infected population in Yunan [22] and CRF07_BC was the predominant strain in Xinjiang Province [23]. However, CRF01_AE were dominant in east China [24,25].…”

Section: Categories Of Antiretroviral Drugs and Susceptibility Of Drumentioning

confidence: 95%

Prevalence of HIV-1 Drug Resistance, Distribution of Subtypes and Drug resistance-associated mutations among Treatment-experienced Individuals in Chengdu, Southwest China, 2014-2016

Chen¹,

Y²,

S³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: The National Free Antiretroviral therapy (ART) Program in China has initiated to provide ART to HIV-1 patients, which may cause problems with drug resistance (DR). The number of HIV/AIDS patients in Chengdu ranks first in the national capital city. However, there is little data on the prevalence of HIV-1 DR in this region. Therefore, epidemiological surveillance was conducted on HIV-1 DR among patients receiving ART in Chengdu. Methods: From 2014 to 2016, HIV/AIDS patients (15 years and older) who had received first-line ART for at least six months were enrolled in this study. Demographic, behavioral information and medical history were recorded, and blood samples were collected for viral loads and immune cell count analyses. HIV-1 pol was amplified, sequenced, and analyzed for HIV-1 subtypes and drug resistance-associated mutations (DRMs). Results: A total of 13,782 individuals were enrolled and 653 cases were considered treatment failure after 6 months of ART. 481 (481/653) samples were amplified and sequenced successfully for subtypes and drug resistance analysis. Six subtypes were identified, among which CRF01_AE (54.3%) and CRF07_BC (41.6%) were the dominant subtypes, and CRF55_01B was detected in Chengdu for the first time. The overall prevalence of HIV-1 DR was 1.8%, with 1.2% to nucleoside reverse transcriptase inhibitors (NRTIs), 1.7% to non-NRTIs (NNRTIs) and 0.14% to protease inhibitors (PIs). The leading DRMs observed in the study were M184I/V (59.59%) against NRTIs and K103N (37.55%) against NNRTIs. Conclusions: This study focused on the HIV-1 molecular surveillance among treatment-experienced individuals in Chengdu. The overall prevalence of DR was relatively low among treated patients. These findings were believed to be contributed to an understanding of HIV-1 subtypes, DR prevalence and DRMs profiles in Chengdu, and thereby optimizing clinical management, prevention and control of HIV.

show abstract

Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals

Cited by 15 publications

References 20 publications

Genetic characterization of HIV-1 viruses among antiretroviral therapy failure individuals in Suzhou City, China

Genetic characterization of HIV-1 viruses among antiretroviral therapy failure individuals in Suzhou City, China

HIV‐1 Drug Resistance, Distribution of Subtypes, and Drug Resistance‐Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014‐2016

Prevalence of HIV-1 Drug Resistance, Distribution of Subtypes and Drug resistance-associated mutations among Treatment-experienced Individuals in Chengdu, Southwest China, 2014-2016

Contact Info

Product

Resources

About